<DOC>
	<DOCNO>NCT02232945</DOCNO>
	<brief_summary>This study aim evaluate efficacy safety nature herbal medicine Banlangen granules patient infected seasonal influenza A ( H1N1 , H3N2 ) influenza B virus .</brief_summary>
	<brief_title>Banlangen Granules Anti-seasonal Influenza Study</brief_title>
	<detailed_description>Inclusion criterion : 1 . Patients confirm influenza A ( H1N1 , H3N2 ) influenza B virus infection real time PCR 2. age 18-65 year old 3. axillary temperature ≥38ºC least two constitutional symptom ( headache , chill , myalgia ，or fatigue ) one respiratory symptom ( cough ，sore throat , coryza ) . 4 . Illness onset within 36 hour , informed consent obtain . Exclusion criterion : 1. age young 18 old 65 year old . 2. patient confirm bronchitis , pneumonia , pleural effusion interstitial lung disease Chest imaging ( chest X-ray CT ) . 3 . Blood routine screening test show numeration leukocyte 10.0×109/L Neutrophil percentage ≥80 % . 4 . Those get suppurative tonsillitis cough purulent sputum . 5 . Those underling primary disorder , hematological disease , chronic obstructive pulmonary disease（FEV1/FVC＜70％，FEV1/ predicate value＜50％； respiratory failure right heart failure）， hepatic disease（ALT AST≥triple ULN） , renal disease（Serum Creatinine＞2mg/dL） , chronic congestive heart failure ( NYHA Ⅲ-IV ) 7 . Patient allergic study medication ( ) . 8 . Women pregnant may possibly become pregnant lactate positive urine pregnant test , obesity ( abody mass index ( BMI ) 25 kg/m2 ) . 9 . Those immunodeficiency , malignant tumor ; Organs bone marrow transplantation ; AIDS ; take immune inhibitor last 3 month . 10 . Doubt alcohol/drug abuse history . 11 . Those participated clinical trial within three month study randomization . 12 . Two week test , acute respiratory Infection，otitis , nasosinusitis . 13 . Those already vaccinate receive influenza vaccine . 14. reason suitable enrollment base investigator 's discretion . The primary efficacy endpoint : 1 . The primary end point duration illness define time onset symptom alleviation ten influenza-like symptom include , nasal obstruction , run nose , cough , sore throat , headache , fatigue , myalgia , chill sweat . 2 . The time defervescence , define time first dose study medication time body temperature decline low 37.4ºC sustain least 24 hour . Secondary efficacy endpoint : The secondary end point include : 1 ) viral shed duration , define time illness onset first time viral nucleic acid test negative ; 2 ) severity disease , assess area curve ( AUC ) analysis total nine influenza-like symptom score , AUC calculate product daily symptom score time duration illness ; 3 ) frequency Usage Acetaminophen ; 4 ) incidence secondary complication influenza , otitis , bronchitis , pneumonia，Nasosinusitis , suppurative tonsillitis , acute parotitis，Reye'ssyndrome，central nervous system disease , Myocarditis pericarditis , acute myositis , toxic shock syndrome.5 ) economic evaluation . Specimen : pharyngeal throat swab，blood . Pharyngea /throat secretion obtain upper respiratory tract patient . All specimen store -80℃ virus laboratory first affiliate hospital guangzhou medical university 5 year .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>confirm influenza A ( H1N1 , H3N2 ) influenza B virus infection real time RTPCR ( rRTPCR ) , age 1865 year old , axillary temperature ≥38ºC least two constitutional symptom ( headache , chill , myalgia ，or fatigue ) one respiratory symptom ( cough ，sore throat , coryza ) . Illness onset within 36 hour , informed consent obtain . 1. age young 18 old 65 year old . 2. patient confirm bronchitis , pneumonia , pleural effusion interstitial lung disease Chest imaging ( chest Xray CT ) . 3 . Blood routine screening test show numeration leukocyte 10.0×109/L Neutrophil percentage ≥80 % . 4 . Those get suppurative tonsillitis cough purulent sputum . 5 . Those underling primary disorder , hematological disease , chronic obstructive pulmonary disease（FEV1/FVC＜70％，FEV1/ predicate value＜50％； respiratory failure right heart failure）， hepatic disease（ALT AST≥triple ULN） , renal disease（Serum Creatinine＞2mg/dL） , chronic congestive heart failure ( NYHA ⅢIV ) 7 . Patient allergic study medication ( ) . 8 . Women pregnant may possibly become pregnant lactate positive urine pregnant test , obesity ( abody mass index ( BMI ) 25 kg/m2 ) . 9 . Those immunodeficiency , malignant tumor ; Organs bone marrow transplantation ; AIDS ; take immune inhibitor last 3 month . 10 . Doubt alcohol/drug abuse history . 11 . Those participated clinical trial within three month study randomization . 12 . Two week test , acute respiratory Infection，otitis , nasosinusitis . 13 . Those already vaccinate receive influenza vaccine . 14.other reason suitable enrollment base investigator 's discretion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>influenza A ( H1N1 , H3N2 )</keyword>
	<keyword>influenza B virus</keyword>
</DOC>